A 
1.54
+7.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Latest on Actinium Pharmaceuticals
Our reporting
- Actinium Pharmaceuticals rises 10.00% in Friday's session
- Actinium Pharmaceuticals falls 3.38% in Monday's session
- Actinium Pharmaceuticals falls 3.27% in Friday's session
- Actinium Pharmaceuticals falls 2.82% in Wednesday's session
- Actinium Pharmaceuticals falls 7.89% in Monday's session
- Actinium Pharmaceuticals falls 5.00% in Friday's session
Next results
Due on 13 Nov 2026. Analysts expect earnings of -0.25 a share on revenue of $1.2m.
Past results
Reported against what analysts expected
| 7 Aug 2026 | 8 May 2026 | 30 Mar 2026 | 14 Nov 2025 | 8 Aug 2025 | 31 Mar 2025 | |
|---|---|---|---|---|---|---|
| Earnings per share | 0.89 | -0.18 | -0.19 | -0.16 | -0.22 | -0.21 |
| Forecast | -0.20 | -0.22 | -0.19 | -0.25 | -0.32 | -0.37 |
| Revenue | $35.0m | — | — | $90,000 | — | $810,000 |
| Forecast | $35.0m | $2.5m | $600,000 | $67,500 | — | — |
Key events
- 11 Aug 202030-to-1 reverse split
- 26 Mar 2014Listed
- 19 Dec 20072-to-1 reverse split
Actinium Pharmaceuticals in the news
Headlines from other publishers, linked to their own pages.
- Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026 (opens Benzinga in a new tab) Benzinga · 17 Feb 2026
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 (opens Yahoo in a new tab) Yahoo · 12 Dec 2025
- Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025 (opens Benzinga in a new tab) Benzinga · 1 Dec 2025
- Actinium To Present New Breast Cancer Data On Its ATNM-400 Radiotherapy At San Antonio Symposium (opens Benzinga in a new tab) Benzinga · 4 Nov 2025
- Actinium Pharmaceuticals are trading higher. The company presented new preclinical data for ATNM-400 antibody radioconjugate at 32nd annual Prostate Cancer Foundation scientific retreat in Carlsbad, California. (opens Benzinga in a new tab) Benzinga · 24 Oct 2025
- Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (opens Yahoo in a new tab) Yahoo · 13 Oct 2025
- Actinium Pharmaceuticals Announces That The First-Ever Preclinical Data From Its ATNM-400 Program In Non-Small Cell Lung Cancer Has Been Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Being Held October 22 – 26, 2025 (opens Benzinga in a new tab) Benzinga · 13 Oct 2025
- Actinium: Q2 Earnings Snapshot (opens Yahoo in a new tab) Yahoo · 8 Aug 2025
Sources and methodology
- Data on this tab
- Our reporting and our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.